ArticleJournal of gastroenterology2019

Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.

Yoshihide Ueda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.